“The Company continues to execute at a high level, including recruitment of 100 patients in our ongoing Halneuron Phase 2b trial and the addition of a, synergistic and complementary pipeline asset, SP16, a novel, first-in-class development candidate for cancer related pain,” said Greg Duncan, Chief Executive Officer of Dogwood (DWTX) Therapeutics. “We are excited for our journey ahead and look forward to delivering on our target milestones, including an update on our interim analysis on our Halneuron CINP Phase 2b trial in Q4 2025, with final data for the full 200 patient data set expected in the second half of 2026, as well as garnering FDA feedback for our proposed SP16 Phase 1b study that is fully funded by the National Cancer Institute.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DWTX:
- Dogwood Therapeutics Announces Business Combination Plans
- Dogwood to present on Halneuron pain research program
- Dogwood files to sell 28.04M shares of common stock for holders
- Strategic Advancements and Growth Potential: Dogwood Therapeutics’ Acquisition of SP16
- Dogwood price target raised to $12 from $10 at H.C. Wainwright